- About Us
- Clinical Trials
- News & Publications
- Business Development
A Phase I/II clinical trial (SP015) was launched in 2018 to test the effects of the combination of DCVAC/PCa and ONCOS-102, which is targeted at prostate cancer patients. This clinical trial is currently being conducted at the Urology Clinic of the University Hospital in Motol, Prague.
Clinical Trial SP015 (Eudra CT: 2015-004314-15) is a Phase I/II, single-arm clinical trial to evaluate the safety and immune activation of the combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming adenovirus, in men with advanced metastatic castration-resistant prostate cancer. This clinical trial has started in May 2018. The planned number of patients enrolled is up to 15. For more information visit www.clinicaltrials.gov .
Only a physician conducting a clinical evaluation of an investigational treatment SOTIO® DCVAC/PCa can include a patient in a clinical trial. If a patient with prostate cancer would like to participate in a trial he can contact participating medical center.
|Medical Center||Address||Department||Clinical Trial Number|
|Fakultní nemocnice v Motole||
V Úvalu 84
|Urology Clinic of Charles University's Second Faculty of Medicine and Motol University Hospital||SP015|